Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730277 | 0.94 | NPC1 (0.57) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL16730279 | 0.93 | NPC1 (0.53) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL17713154 | 0.87 | CNR1 (0.49) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL18383369 | 0.87 | CNR1 (0.62) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL18058762 | 0.81 | HDAC8 (0.41) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL18058760 | 0.80 | PTGS2 (0.41) | MAPTMAPK1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL18028145 | 0.79 | NPC1 (0.45) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL18028138 | 0.79 | MAPT (0.45) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL21890845 | 0.78 | RPS6KA3 (0.40) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL16730425 | 0.78 | MAPT (0.44) | MAPTNPC1RAB9AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | PEPD, F2, XDH | MAPT 4645/4885NPC1 3778/4885RAB9A 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.